Aethlon Medical, Inc. (AEMD)
| Previous Close | 1.28 |
| Open | 1.30 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 3100 |
| Day's Range | 1.26 - 1.35 |
| 52 Week Range | 0.79 - 3.85 |
| Volume | 129,625 |
| Avg. Volume | 225,475 |
| Market Cap | 23.445M |
| Beta | 2.41 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.60 |
| Earnings Date | Feb 9, 2018 - Feb 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.00 |
- PR Newswire•4 days ago
Aethlon Medical Announces Fiscal 2018 Results
SAN DIEGO , June 8, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
- PR Newswire•13 days ago
Aethlon Medical To Release 2018 Fiscal Year End Financial Results and Host Conference Call on June 8, 2018
Also Presenting at 2018 BIO International Convention on June 6, 2018 SAN DIEGO , May 31, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs ...
- Simply Wall St.•19 days ago
Are Aethlon Medical Inc’s (NASDAQ:AEMD) Interest Costs Too High?
Aethlon Medical Inc (NASDAQ:AEMD) is a small-cap stock with a market capitalization of US$21.04M. While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, theyRead More...
- GlobeNewswire•last month
Report: Developing Opportunities within AMC Networks, JELD-WEN Holding, Blueprint Medicines, Northwest Bancshares, Anika Therapeutics, and Aethlon Medical — Future Expectations, Projections Moving into 2018
NEW YORK, May 01, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of AMC ...
- ACCESSWIRE•2 months ago
GVC Capital and Trickle Research Announce Presenter Schedule for Rocky Mountain MicroCap Conference II in Denver on April 24, 2018
DENVER, CO / ACCESSWIRE / April 20, 2018 / GVC Capital LLC ("GVC") and Dave Lavigne at Trickle Research LLC ("Trickle Research") will host the Rocky Mountain MicroCap Conference II ...
- PR Newswire•3 months ago
Study of Blood Test to Detect and Monitor Chronic Traumatic Encephalopathy (CTE) in Former NFL Players Set for Kick-Off in Phoenix
PHOENIX and SAN DIEGO, March 22, 2018 /PRNewswire/ -- Exosome Sciences, Inc., a diagnostic subsidiary of Aethlon Medical, Inc. (AEMD), today announced the initiation of an Institutional Review Board (IRB) approved protocol for a research study involving retired NFL players and a data-supported biomarker candidate to potentially detect and monitor Chronic Traumatic Encephalopathy (CTE) in living individuals. The sample collection will be conducted in collaboration with Kendall Van Keuren-Jensen, Ph.D., co-director of the Translational Genomics Research Institute's (TGen) Center for Noninvasive Diagnostics, for biomarker discovery projects. With the approval of the protocol, investigators plan to initiate screening of candidate participants in the coming weeks. The study will enroll former NFL players, who are at high-risk of suffering from CTE, and control subjects who didn't participate in activities that involved repetitive head trauma.
- GlobeNewswire•3 months ago
Research Report Identifies Chatham Lodging Trust (REIT), Independent Bank Group, NeoGenomics, Black Knight, Aethlon Medical, and PRA Group with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, March 19, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
- PR Newswire•4 months ago
Aethlon Medical To Present at the American Society for Microbiology Biothreats Meeting
SAN DIEGO, Feb. 12, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, announced today that its CEO, Jim Joyce will give a presentation at the 2018 American Society for Microbiology (ASM) Biothreats Meeting. The presentation entitled: "A Broad-Spectrum Platform to Address Life-Threating Viral Infections," is scheduled to begin at 8:30am eastern on February 14th. The presentation slide-deck will be made available on the Aethlon Medical website at https://www.aethlonmedical.com/news-media/presentations. The American Society for Microbiology Biothreats Meeting is being held today, February 12th through the 14th at the Hilton, Baltimore Md. The event includes tracks on high consequence pathogen research, biological threat reduction, product development, and policy.
- Zacks Small Cap Research•4 months ago
AEMD: Q3 Results. Hemopurifier Pathway Could Benefit From New FDA Mindset
By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2018 Financials, Operational Update Aethlon Medical (NASDAQ:AEMD) reported financial results for their fiscal third quarter 2018 ending December 31st and provided ...
- PR Newswire•4 months ago
Aethlon Medical Announces Fiscal 2018 Third Quarter Results
SAN DIEGO , Feb. 1, 2018 /PRNewswire/ -- Aethlon Medical, Inc. (Nasdaq: AEMD), a therapeutic technology company focused on unmet needs in global health and biodefense, today announced results for its fiscal ...
Upgrades & Downgrades
| Initiated | H.C. Wainwright: to Buy | 11/20/2017 |
Company Profile
9635 Granite Ridge Drive
Suite 100
San Diego, CA 92123
United States
858-459-7800
http://www.aethlonmedical.com
Sector: Technology
Industry: Scientific & Technical Instruments
Full Time Employees: 6
Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device for the single-use removal of life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosome-based products to diagnose and monitor neurological disorders and cancer; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.
